Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Chi-Med, Innovent enter global cancer partnership

Alicia Parker
November 30, 2018 9:59 PM UTC

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) and Innovent Biologics Inc. (HKSE:1801) will take advantage of China’s new foreign data guidelines and enter into a global partnership to develop fruquintinib in combination with sintilimab to treat advanced solid tumors.

The companies said the new foreign data guidelines, which allow companies to submit foreign clinical data to support Chinese regulatory submissions, could expedite the path to a China launch (see “China Accelerates Drug Review Timelines for Rare, Life-Threatening Diseases")...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Hutchison China MediTech Ltd.

Innovent Biologics Inc.